← FDA DRUG APPROVALS

FDA NDA · NDA020178

SODIUM CHLORIDE

Sponsor: BAXTER HLTHCARE

APPLICATION
NDA020178
TYPE
NDA
ORIGINAL APPROVAL
1992-12-07
LATEST ACTION
2022-12-07
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · ReferencePrescription
SODIUM CHLORIDE 900MG/100ML · SOLUTION · INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · ReferencePrescription
SODIUM CHLORIDE 450MG/50ML (9MG/ML) · SOLUTION · INJECTION

Approval history

2022-12-07Manufacturing (CMC) · Supplement 31LetterAP
2020-01-27Manufacturing (CMC) · Supplement 23LetterAP
2019-05-29Labeling · Supplement 21 · standardLabelAP
2015-11-23Labeling · Supplement 13 · standardLetterAP
2015-07-28Manufacturing (CMC) · Supplement 15 · standardAP
2001-05-04Manufacturing (CMC) · Supplement 6 · standardAP
1999-09-14Labeling · Supplement 5AP
1997-12-29Manufacturing (CMC) · Supplement 4 · standardAP
1994-09-30Manufacturing (CMC) · Supplement 1 · standardAP
1994-07-15Manufacturing (CMC) · Supplement 3 · standardAP
1994-02-18Manufacturing (CMC) · Supplement 2 · standardAP
1992-12-07Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →